155 related articles for article (PubMed ID: 32101626)
1. Hyperparathyroidism in Patients With X-Linked Hypophosphatemia.
Lecoq AL; Chaumet-Riffaud P; Blanchard A; Dupeux M; Rothenbuhler A; Lambert B; Durand E; Boros E; Briot K; Silve C; Francou B; Piketty M; Chanson P; Brailly-Tabard S; Linglart A; Kamenický P
J Bone Miner Res; 2020 Jul; 35(7):1263-1273. PubMed ID: 32101626
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report.
Takashi Y; Toyokawa K; Oda N; Muta Y; Yokomizo H; Fukumoto S; Kawanami D
Front Endocrinol (Lausanne); 2022; 13():1004624. PubMed ID: 36531500
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in pediatric metabolic bone disease: the consequences of altered phosphate homeostasis in renal insufficiency and hypophosphatemic vitamin D-resistant rickets.
Pettifor JM
Bone Miner; 1990 Jun; 9(3):199-214. PubMed ID: 2163713
[TBL] [Abstract][Full Text] [Related]
4. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status.
Carpenter TO; Insogna KL; Zhang JH; Ellis B; Nieman S; Simpson C; Olear E; Gundberg CM
J Clin Endocrinol Metab; 2010 Nov; 95(11):E352-7. PubMed ID: 20685863
[TBL] [Abstract][Full Text] [Related]
5. Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia: a randomized, double-blind, placebo-controlled study.
Carpenter TO; Olear EA; Zhang JH; Ellis BK; Simpson CA; Cheng D; Gundberg CM; Insogna KL
J Clin Endocrinol Metab; 2014 Sep; 99(9):3103-11. PubMed ID: 25029424
[TBL] [Abstract][Full Text] [Related]
6. PHEX expression in parathyroid gland and parathyroid hormone dysregulation in X-linked hypophosphatemia.
Blydt-Hansen TD; Tenenhouse HS; Goodyer P
Pediatr Nephrol; 1999 Sep; 13(7):607-11. PubMed ID: 10460513
[TBL] [Abstract][Full Text] [Related]
7. Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients.
DeLacey S; Liu Z; Broyles A; El-Azab SA; Guandique CF; James BC; Imel EA
Bone; 2019 Oct; 127():386-392. PubMed ID: 31276850
[TBL] [Abstract][Full Text] [Related]
8. The enigma of hyperparathyroidism in hypophosphatemic rickets.
Schmitt CP; Mehls O
Pediatr Nephrol; 2004 May; 19(5):473-7. PubMed ID: 15015068
[TBL] [Abstract][Full Text] [Related]
9. Disease Manifestations and Complications in Dutch X-Linked Hypophosphatemia Patients.
Bosman A; Appelman-Dijkstra NM; Boot AM; de Borst MH; van de Ven AC; de Jongh RT; Bökenkamp A; van den Bergh JP; van der Eerden BCJ; Zillikens MC
Calcif Tissue Int; 2024 Mar; 114(3):255-266. PubMed ID: 38226986
[TBL] [Abstract][Full Text] [Related]
10. Plasma intact fibroblast growth factor 23 level is a useful tool for diagnostic approach of renal hypophosphatemia.
Giralt M; Chocron S; Ferrer R; Ariceta G
Pediatr Nephrol; 2021 Apr; 36(4):1025-1028. PubMed ID: 33492457
[TBL] [Abstract][Full Text] [Related]
11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
12. A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet.
Raeder H; Shaw N; Netelenbos C; Bjerknes R
Eur J Endocrinol; 2008 Dec; 159 Suppl 1():S101-5. PubMed ID: 18775977
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia.
Carpenter TO; Imel EA; Ruppe MD; Weber TJ; Klausner MA; Wooddell MM; Kawakami T; Ito T; Zhang X; Humphrey J; Insogna KL; Peacock M
J Clin Invest; 2014 Apr; 124(4):1587-97. PubMed ID: 24569459
[TBL] [Abstract][Full Text] [Related]
14. Renal Phosphate Handling: Independent Effects of Circulating FGF23, PTH, and Calcium.
McKenna MJ; Crowley RK; Twomey PJ; Kilbane MT
JBMR Plus; 2021 Feb; 5(2):e10437. PubMed ID: 33615106
[TBL] [Abstract][Full Text] [Related]
15. Increased prevalence of primary hyperparathyroidism in treated breast cancer.
Fierabracci P; Pinchera A; Miccoli P; Conte PF; Vignali E; Zaccagnini M; Marcocci C; Giani C
J Endocrinol Invest; 2001 May; 24(5):315-20. PubMed ID: 11407650
[TBL] [Abstract][Full Text] [Related]
16. 1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression.
Liu ES; Martins JS; Raimann A; Chae BT; Brooks DJ; Jorgetti V; Bouxsein ML; Demay MB
J Bone Miner Res; 2016 May; 31(5):929-39. PubMed ID: 26751835
[TBL] [Abstract][Full Text] [Related]
17. Management of X-linked hypophosphatemia in adults.
Lecoq AL; Brandi ML; Linglart A; Kamenický P
Metabolism; 2020 Feb; 103S():154049. PubMed ID: 31863781
[TBL] [Abstract][Full Text] [Related]
18. Co-existence of X-linked hypophosphatemic rickets (XLH) and primary hyperparathyroidism: case report and review of the literature.
Tournis ST; Giannikou PV; Paspati IN; Katsalira EA; Voskaki IC; Lyritis GP
J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):150-4. PubMed ID: 15951631
[TBL] [Abstract][Full Text] [Related]
19. Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review.
Yavropoulou MP; Kotsa K; Gotzamani Psarrakou A; Papazisi A; Tranga T; Ventis S; Yovos JG
Hormones (Athens); 2010; 9(3):274-8. PubMed ID: 20688626
[TBL] [Abstract][Full Text] [Related]
20. Secondary hyperparathyroidism after removal of a parathyroid adenoma.
Jiménez-Montero JG; Lobo-Hernández E; Picado-Larios A; Molina MA
Endocr Pract; 2002; 8(6):429-32. PubMed ID: 15260008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
